Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01810783 · ClinicalTrials.gov registry record · Phase 3
Brexpiprazole in Patients With Schizophrenia
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 210
- Enrollment target
NCT01810783: Completed Phase 3 study, sponsored by H. Lundbeck A/S.
NCT01810783 is a Phase 3 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 210 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01810783, a Phase 3 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 210 participants
- Enrollment target
Study Summary
To determine the safety and efficacy of brexpiprazole during long-term treatment.
Primary Outcome
Number of treatment-emergent adverse events (TEAEs)
Interventions
- DRUG Brexpiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
What the finished NCT01810783 record still lists
NCT01810783 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 1 intervention - of which Brexpiprazole is the first listed.
NCT01810783 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01810783 about?
NCT01810783 is a clinical study titled "Brexpiprazole in Patients With Schizophrenia". To determine the safety and efficacy of brexpiprazole during long-term treatment.
What is the current status of trial NCT01810783?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 210 participants. The study started on 2013-07. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01810783?
The interventions under investigation include: Brexpiprazole (DRUG).
Who is sponsoring clinical trial NCT01810783?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01810783's enrollment target sits among peer trials
210 1338th of 2000 higher than 656 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia